The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer
Official Title: A SINGLE ARM PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF Nab®-PACLITAXEL, IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER
Study ID: NCT02103062
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer. Subjects will be placed into two separate cohorts based on their RAS mutation status.
Detailed Description: ABI-007-COLO-001 is a Phase 2, single arm, open label, multicenter study to evaluate the efficacy and safety of Abraxane (nab-paclitaxel) given on days 1, 8 and 15 of a 28 day cycle in subjects with previously treated metastatic colorectal cancer. Subjects will be enrolled into cohorts by RAS mutation status (wildtype or mutated). Stage 1 in a given cohort will enroll 15 subjects in the Intention to Treat population and if more than 8 subjects have Progression Free Survival at the 8 week assessment, then Stage 2 will open in the respective cohort. Stage 2 will enroll an additional 28 subjects for a total of 43 subjects in each cohort. The study will be positive if more than 26 subjects with Progression Free Survival at the 8 week assessment are observed in 43 subjects per cohort. Interim analysis after Stage 1 did not meet protocol defined criteria to proceed to Stage 2. Patients currently enrolled will be followed for Progression Free Survival and until 28 days after last dose, secondary endpoints including overall survival will not be followed
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Oscar Lambret, Dept. de Cancerologie Digestive et Urologique, Lille 59, , France
Centre Regional de Lutte contre le Cancer Val d'Aurelle, Montpellier cedex 5, , France
CRLCC Centre Rene Gauducheau, Saint Herblain 44, , France
Institut Curie, Saint-Cloud, , France
Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, , France
Institut Gustave Roussy Hematologie, Villejuif, , France
Name: Alfredo Romano, MD
Affiliation: Celgene
Role: STUDY_DIRECTOR